87
Participants
Start Date
March 8, 2021
Primary Completion Date
November 1, 2023
Study Completion Date
November 6, 2023
Midomafetamine HCl
Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.
NYU, New York
New York Private Practice, New York
Zen Therapeutic Solutions, LLC, Mt. Pleasant
Ray Worthy Psychiatry, New Orleans
Aguazul-Blue Water Inc., Boulder
Wholeness Center, Fort Collins
New School Research, Los Angeles
San Francisco Insight and Integration Center, San Francisco
UCSF, San Francisco
Trauma Research Foundation, Boston
University of Wisconsin - Madison, Madison
Numinus, Vancouver
Numinus, Montreal
Beer Yaakov Mental Health Center, Beer Yaaqov
Tel Hashomer, Tel Aviv
Lead Sponsor
Lykos Therapeutics
INDUSTRY